Hepatocellular carcinoma (HCC) is the most common primary liver cancer accounting for approximately 90% of cases and is strongly associated with chronic liver diseases such as cirrhosis. A biologically relevant, predictive, and user-friendly HCC model is required to expedite research and develop novel therapies.
In this poster, we present the development of a screenable vascularized HCC model in the OrganoPlate® Graft using patient-derived material. This perfusable microvascular network is responsive to standard of care drugs and allows for phenotypic assessment of the vasculature organization. Here, we accomplished high-throughput screening of 30 treatment conditions, including Sorafenib and Lenvatinib, and performed vascular bed- and cytokine analysis.
Download the poster here